NCT05884333
Cord Blood Transplant in Adults With Blood Cancers
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 6 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 20 words
- Enrollment closed, study ongoing
- Final enrollment: 17 participants (planned 54)
- Site details revised
- Minor Site contact updatedv8
- Study Identification, Study Status, Oversightv6
- Notable Eligibility criteria shortened, about 60 words
- Study sites: 7 to 1
- Notable Eligibility criteria expanded, about 33 wordsv4
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
Adult patients with high-risk hematologic malignancies and a suitable double-unit CB graft will undergo work-up to assess protocol eligibility. CB graft selection will be based on established MSKCC guidelines. Patients will receive standard conditioning with Cy 50 mg/kg, Flu 150 mg/m2, Thio 10 mg/kg, and TBI 400 cGy according to the eligibility criteria. GVHD prophylaxis will consist of CSA and MMF starting day -3. The double-unit CB graft will be infused on day 0 per standard practice. Optimized CBT practices, will be implemented in this protocol.
Drugs: Conditioning Chemotherapy
Biologicals: Cord blood graft
Sites
1 site in 1 country
- Memorial Sloan Kettering Cancer CenterNew York, New York, United States